**CLAIM AMENDMENTS:**

**This listing of claims will replace all prior versions and listing of claims in the application.**

**Listing of the Claims:**

Claim 1 (**currently amended**): A quinazoline derivative of the Formula I:



I

wherein:

one of $R^{1a}$ or $R^{1b}$ is a group of sub-formula (i)

$$Q^2\text{-}X^1\text{-}Z\text{-}Q^1\text{-}X^2\text{-}O\text{-}$$

(i)

where $X^2$ and $X^1$ are independently selected from a direct bond or a group $-[CR^4R^5]_m$, wherein m is an integer from 1 to 6,

Z is C(O), $SO_2$, $-C(O)NR^{10}$-, $-N(R^{10})C(O)$-, -C(O)O- or –OC(O)- where $R^{10}$ is hydrogen or (1-6C)alkyl,

and each of $R^4$ and $R^5$ is independently selected from hydrogen, hydroxy, (1-4C)alkyl, halo(1-4C)alkyl, hydroxy (1-4C)alkyl, (1-4C)alkoxy(1-4C)alkyl, or $R^4$ and $R^5$ together with the carbon atom(s) to which they are attached form a (3-7)cycloalkyl ring, provided that when a group $R^4$ or $R^5$ is hydroxy, m is at least 2 and the carbon atom to which the hydroxy group is attached is not also attached to another oxygen or a nitrogen atom;

**$Q^1$** is a piperidinyl ring ~~(3-7C)cycloalkylene or heterocyclyl group~~, which is optionally substituted by one or two substituents selected from halogeno, trifluoromethyl, trifluoromethoxy,

cyano, nitro, hydroxy, amino, carboxy, carbamoyl, acryloyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (2-6C)alkenylthio, (2-6C)alkynylthio, (1-6C)alkylsulfinyl, (2-6C)alkenylsulfinyl, (2-6C)alkynylsulfinyl, (1-6C)alkylsulfonyl, (2-6C)alkenylsulfonyl, (2-6C)alkynylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, sulfamoyl, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino, N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, carbamoyl(1-6C)alkyl, N-(1-6C)alkylcarbamoyl(1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl(1-6C)alkyl, sulfamoyl(1-6C)alkyl, N-(1-6C)alkylsulfamoyl(1-6C)alkyl, N,N-di-[(1-6C)alkyl]sulfamoyl(1-6C)alkyl, (2-6C)alkanoyl(1-6C)alkyl, (2-6C)alkanoyloxy(1-6C)alkyl, (2-6C)alkanoylamino(1-6C)alkyl, N-(1-6C)alkyl-(2-6C)alkanoylamino(1-6C)alkyl and (1-6C)alkoxycarbonyl(1-6C)alkyl;

$Q^2$ is an isoxazolyl ring ~~aryl or heteroaryl group, said aryl or heteroaryl group being~~ optionally substituted by one of more substituents selected from halogeno, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, acryloyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (2-6C)alkenylthio, (2-6C)alkynylthio, (1-6C)alkylsulfinyl, (2-6C)alkenylsulfinyl, (2-6C)alkynylsulfinyl, (1-6C)alkylsulfonyl, (2-6C)alkenylsulfonyl, (2-6C)alkynylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, sulfamoyl, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino, N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, carbamoyl(1-6C)alkyl, N-(1-6C)alkylcarbamoyl(1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl(1-6C)alkyl, sulfamoyl(1-6C)alkyl, N-(1-6C)alkylsulfamoyl(1-6C)alkyl, N,N-di-[(1-6C)alkyl]sulfamoyl(1-6C)alkyl, (2-6C)alkanoyl(1-6C)alkyl, (2-6C)alkanoyloxy(1-6C)alkyl, (2-6C)alkanoylamino(1-6C)alkyl,

N-(1-6C)alkyl-(2-6C)alkanoylamino(1-6C)alkyl and (1-6C)alkoxycarbonyl(1-6C)alkyl,

and wherein any (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (2-6C)alkanoyl substituent on $Q^1$ or $Q^2$ optionally bears one or more substituents ~~(for example 1, 2 or 3)~~ which may be the same or different selected from halogeno, hydroxy and (1-6C)alkyl and/or optionally a substituent selected from cyano, nitro, carboxy, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, hydroxy(1-6C)alkoxy, (1-4C)alkoxy(1-6C)alkoxy, (2-6C)alkanoyl, (2-6C)alkanoyloxy and $NR^aR^b$, wherein $R^a$ is hydrogen or (1-4C)alkyl and $R^b$ is hydrogen or (1-4C)alkyl, and wherein any (1-4C)alkyl in $R^a$ or $R^b$ optionally bears one or more substituents ~~(for example 1, 2 or 3)~~ which may be the same or different selected from halogeno and hydroxy and/or optionally a substituent selected from cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, hydroxy(1-4C)alkoxy and (1-2C)alkoxy(1-4C)alkoxy,

or $R^a$ and $R^b$ together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring, which optionally bears 1 or 2 substituents, which may be the same or different, on an available ring carbon atom selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy , and may optionally bear on any available ring nitrogen a substituent (provided the ring is not thereby quaternised) selected from (1-4C)alkyl, (2-4C)alkanoyl and (1-4C)alkylsulfonyl,

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by $R^a$ and $R^b$ together with the nitrogen atom to which they are attached, optionally bears one or more substituents ~~(for example 1, 2 or 3)~~ which may be the same or different selected from halogeno and hydroxy and/or optionally a substituent selected from (1-4C)alkyl and (1-4C)alkoxy;

and wherein $Q^1$ ~~any heterocyclyl group $Q^+$ group~~ optionally bears 1 or 2 oxo (=O) or thioxo (=S) substituents;

and the other of $R^{1a}$ or $R^{1b}$ is a group $R^1$ which is selected from hydrogen, hydroxy, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, or a group of the formula :

$$Q^4\text{-}X^3\text{-}$$

wherein $X^3$ is a direct bond or is selected from O or S, and $Q^4$ is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl

or heterocyclyl-(1-6C)alkyl,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a $R^1$ substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, $SO_2$, $N(R^4)$, CO, $CH(OR^4)$, $CON(R^4)$, $N(R^4)CO$, $SO_2N(R^4)$, $N(R^4)SO_2$, CH=CH and C≡C wherein $R^4$ is hydrogen or (1-6C)alkyl,

and wherein any $CH_2$=CH- or HC≡C- group within a $R^1$ substituent optionally bears at the terminal $CH_2$= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :

$$Q^5\text{-}X^4\text{-}$$

wherein $X^4$ is a direct bond or is selected from CO and $N(R^5)CO$, wherein $R^5$ is hydrogen or (1-6C)alkyl, and $Q^5$ is heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any alkyl or alkylene group within a $R^1$ substituent optionally bears one or more halogeno, (1-6C)alkyl, hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, or from a group of the formula:

$$\text{-}X^5\text{-}Q^6$$

wherein $X^5$ is a direct bond or is selected from O, S, SO, $SO_2$, $N(R^6)$, CO, $CH(OR^6)$, $CON(R^6)$, $N(R^6)CO$, $SO_2N(R^6)$, $N(R^6)SO_2$, $C(R^6)_2O$, $C(R^6)_2S$ and $C(R^6)_2N(R^6)$, wherein $R^6$ is hydrogen or (1-6C)alkyl, and $Q^6$ is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on $R^1$ optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano,

nitro, hydroxy, amino, carboxy, carbamoyl, formyl, mercapto, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino, and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, or from a group of the formula:

$$-X^6-R^7$$

wherein $X^6$ is a direct bond or is selected from O, N($R^8$) and C(O), wherein $R^8$ is hydrogen or (1-6C)alkyl, and $R^7$ is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, (2-6C)alkanoyl-(1-6C)alkyl or (1-6C)alkoxycarbonyl-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on $R^1$ optionally bears 1 or 2 oxo or thioxo substituents;

$R^2$ is selected from hydrogen and (1-6C)alkyl;

each $R^3$, which may be the same or different, is selected from halogeno, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, trifluoromethyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, N-(1-6C)alkylsulfamoyl, and N,N-di-[(1-6C)alkyl]sulfamoyl

a is 1, 2, 3, 4 or 5;

or a pharmaceutically acceptable salt thereof;

subject to ~~the following provisos:~~

~~(i) when $Q^2$ is aryl, then $R^{1a}$ is a group of sub-formula (i) defined above and $R^{1b}$ is the group $R^1$ defined above; and~~

~~(ii)~~ the proviso that the compound of formula I is not ~~one of the following:~~

N-(3,4-dichlorophenyl)-7-[({4-[(3,5-dimethylisoxazol-4-yl)carbonyl]morpholin-2-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine~~;~~

~~N-(3,4-dichlorophenyl)-7-({[4-(furan-3-ylcarbonyl)morpholin-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;~~

~~7-[({4-[(2-chloropyridin-3-yl)carbonyl]morpholin-2-yl}methyl)oxy]-N-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine; or~~

~~7-[({4-[(6-chloropyridin-3-yl)carbonyl]morpholin-2-yl}methyl)oxy]-N-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine~~.

Claim 2 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~any one of the preceding claims~~ wherein $X^2$ is a direct bond.

Claim 3 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~or claim 2~~, wherein $R^{1a}$ is a group of sub-formula (i), and $R^{1b}$ is a group $R^1$ as defined in claim 1.

Claim 4 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~or claim 2~~, wherein $R^{1a}$ is a group $R^1$, and $R^{1b}$ is a group of sub-formula (i) as defined in claim 1.

Claim 5 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~any one of the preceding claims~~, wherein $R^1$ is selected from hydrogen, hydroxy, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, or a group of the formula :

$$Q^4\text{-}X^3\text{-}$$

wherein $X^3$ is a direct bond or is O or S ~~(particularly a direct bond or O)~~, and $Q^4$ is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, and wherein any alkyl or alkylene group within a $R^1$ substituent optionally bears one or more

halogeno, (1-6C)alkyl, hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino.

Claim 6 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 5 wherein $R^1$ is hydrogen, (1-6C)alkoxy and (1-4C)alkoxy(1-6C)alkoxy, and wherein any (1-6C)alkoxy group within $R^1$ optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from hydroxy, fluoro and chloro.

Claim 7 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 6 wherein $R^1$ is selected from methoxy, ethoxy, isopropyloxy, cyclopropylmethoxy, 2-hydroxyethoxy, 2-fluoroethoxy, 2-methoxyethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy or 3-hydroxy-3-methylbutoxy.

Claim 8 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 5 wherein $R^1$ is methoxy.

Claim 9 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~any one of the preceding claims~~ wherein $X^1$ is suitably a direct bond or a (1-6C)alkylene group.

Claim 10 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 9 wherein $X^1$ is a direct bond or methylene or ethylene group.

Claim 11 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~any one of the preceding claims~~ wherein Z is selected from -C(O)-, $-NR^{10}-C(O)-$ (wherein $R^{10}$ is H or (1-6C)alkyl), and –O-C(O)-.

Claim 12 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 11, wherein Z is -C(O)-.

Claim 13 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 11, wherein Z is selected from
-NH-C(O)- and –O-C(O)-.

Claims 14-15 (**cancelled**).

Claim 16 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 11 ~~any one of claims 11 to 16~~, wherein the group $Q^2$-$X^1$-Z- is linked to the piperidinyl nitrogen ~~a nitrogen atom on a heterocyclic atom~~ of $Q^1$.

Claim 17 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~any one of the preceding claims~~, wherein $Q^2$ is ~~a heteroaryl group, said heteroaryl group being~~ optionally substituted by one of more substituents selected from halogeno, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, acryloyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (2-6C)alkenylthio, (2-6C)alkynylthio, (1-6C)alkylsulfinyl, (2-6C)alkenylsulfinyl, (2-6C)alkynylsulfinyl, (1-6C)alkylsulfonyl, (2-6C)alkenylsulfonyl, (2-6C)alkynylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, sulfamoyl, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino, N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, carbamoyl(1-6C)alkyl, N-(1-6C)alkylcarbamoyl(1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl(1-6C)alkyl, sulfamoyl(1-6C)alkyl, N-(1-6C)alkylsulfamoyl(1-6C)alkyl, N,N-di-[(1-6C)alkyl]sulfamoyl(1-6C)alkyl, (2-6C)alkanoyl(1-6C)alkyl,

(2-6C)alkanoyloxy(1-6C)alkyl, (2-6C)alkanoylamino(1-6C)alkyl, N-(1-6C)alkyl-(2-6C)alkanoylamino(1-6C)alkyl and (1-6C)alkoxycarbonyl(1-6C)alkyl,

and wherein any (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (2-6C)alkanoyl substituent on $Q^2$ optionally bears one or more substituents ~~(for example 1, 2 or 3)~~ which may be the same or different selected from halogeno, hydroxy and (1-6C)alkyl and/or optionally a substituent selected from cyano, nitro, carboxy, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, hydroxy(1-6C)alkoxy, (1-4C)alkoxy(1-6C)alkoxy, (2-6C)alkanoyl, (2-6C)alkanoyloxy and $NR^aR^b$, wherein $R^a$ is hydrogen or (1-4C)alkyl and $R^b$ is hydrogen or (1-4C)alkyl, and wherein any (1-4C)alkyl in $R^a$ or $R^b$ optionally bears one or more substituents ~~(for example 1, 2 or 3)~~ which may be the same or different selected from halogeno and hydroxy and/or optionally a substituent selected from cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, hydroxy(1-4C)alkoxy and (1-2C)alkoxy(1-4C)alkoxy,

or $R^a$ and $R^b$ together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring, which optionally bears 1 or 2 substituents, which may be the same or different, on an available ring carbon atom selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy , and may optionally bear on any available ring nitrogen a substituent (provided the ring is not thereby quaternised) selected from (1-4C)alkyl, (2-4C)alkanoyl and (1-4C)alkylsulfonyl,

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by $R^a$ and $R^b$ together with the nitrogen atom to which they are attached, optionally bears one or more substituents ~~(for example 1, 2 or 3)~~ which may be the same or different selected from halogeno and hydroxy and/or optionally a substituent selected from (1-4C)alkyl and (1-4C)alkoxy.

Claims 18-22 (**cancelled**).

Claim 23 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~any one of the preceding claims~~ wherein $Q^2$ optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, hydroxy, nitro, amino, cyano, carbamoyl, (1-4C)alkyl,

(1-4C)alkoxy, (2-4C)alkanoyl and (1-4C)alkylsulfonyl, (1-4C)alkylamino, di[(1-4C)alkyl]amino, *N*-[(1-4C)alkyl]carbamoyl, and *N,N*-di[(1-4C)alkyl]carbamoyl.

and wherein any (1-4C)alkyl, or (2-4C)alkanoyl group within $Q^2$ optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, hydroxy and (1-6C)alkyl and/or optionally a substituent selected from cyano, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkanoyl, (2-6C)alkanoyloxy and $NR^aR^b$, wherein $R^a$ is hydrogen or (1-4C)alkyl and $R^b$ is hydrogen or (1-4C)alkyl, and wherein any (1-4C)alkyl in $R^a$ or $R^b$ optionally bears one or more substituents ~~(for example 1, 2 or 3)~~ which may be the same or different selected from halogeno and hydroxy and/or optionally a substituent selected from cyano, and (1-4C)alkoxy,

or $R^a$ and $R^b$ together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which does not contain oxygen, which ring optionally bears 1 or 2 substituents, which may be the same or different, on an available ring carbon atom selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy, and may optionally bear on any available ring nitrogen a substituent (provided the ring is not thereby quaternised) selected from (1-4C)alkyl, (2-4C)alkanoyl and (1-4C)alkylsulfonyl,

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by $R^a$ and $R^b$ together with the nitrogen atom to which they are attached optionally bears one or more substituents ~~(for example 1, 2 or 3)~~, which may be the same or different, selected from halogeno and hydroxy and/or optionally a substituent selected from (1-4C)alkyl and (1-4C)alkoxy.

Claim 24 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 23 wherein $Q^2$ is optionally substituted by one or two groups, which may be the same or different, selected from halogeno, hydroxy, nitro, amino, cyano, carbamoyl, (1-4C)alkyl, (1-4C)alkoxy, (2-4C)alkanoyl and (1-4C)alkylsulfonyl, [(1-4C)alkyl]amino, di[(1-4C)alkyl]amino, *N*-[(1-4C)alkyl]carbamoyl, and *N,N*-di[(1-4C)alkyl]carbamoyl.

and wherein any (2-4C)alkanoyl group in a substituent on $Q^2$ optionally bears one or two substituents, which may be the same or different, selected from hydroxy and (1-3C)alkyl,

and wherein any (1-4C)alkyl group in a substituent on $Q^2$ optionally bears one or two substituents, which may be the same or different, selected from hydroxy, (1-4C)alkoxy and halogeno ~~(particularly chloro and more particularly fluoro)~~.

Claim 25 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 23 ~~or claim 24~~ wherein $Q^2$ is unsubstituted or substituted by a (1-4C)alkyl group, a (1-4C)alkoxy group, halogeno, amino, nitro, cyano, carbamoyl, di-[(1-4C)alkyl]amino, and *N,N*-di[(1-4C)alkyl]carbamoyl.

Claim 26 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~any one of the preceding claims~~ wherein $R^2$ is hydrogen.

Claim 27 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~any one of the preceding claims~~ wherein a is 1, 2 or 3.

Claim 28 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~any one of the preceding claims~~, wherein an $R^3$ is in the para position on the anilino ring, and this is selected from halogeno, cyano, nitro, hydroxy, amino, trifluoromethyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylamino and di-[(1-6C)alkyl]amino.

Claim 29 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 1 ~~any one of the preceding claims~~ wherein the group of sub-formula (ii)




(ii)

in formula (I) is a group of sub-formula (iii)




(iii)

where one of $R^{15}$ or $R^{17}$ is hydrogen and the other is halogeno, and $R^{16}$ is halogeno.

Claim 30 (**currently amended**): The ~~A~~ quinazoline derivative according to claim 29 wherein the group of sub-formula (iii) is 3-chloro-2-fluorophenyl, or 3-chloro-4-fluorophenyl.

Claim 31 (**currently amended**): The ~~A~~ compound according to claim 1 selected from one of the following:

(1) *N*-(3-chloro-2-fluorophenyl)-6-{[1-(isoxazol-5-ylcarbonyl)piperidin-4-yl]oxy}-7-methoxyquinazolin-4-amine;

(2) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-({1-[(3-methylisoxazol-5-yl)acetyl]piperidin-4-yl}oxy)quinazolin-4-amine;

(3) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-({1-[(3-methylisoxazol-5-yl)carbonyl]piperidin-4-yl}oxy)quinazolin-4-amine;

(4) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-({1-[(5-methylisoxazol-3-yl)carbonyl]piperidin-4-yl}oxy)quinazolin-4-amine;

(5) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-({1-[(5-methylisoxazol-4-yl)carbonyl]piperidin-4-yl}oxy)quinazolin-4-amine;

(6) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-({1-[(3-methylisoxazol-4-yl)carbonyl]piperidin-4-yl}oxy)quinazolin-4-amine;

(7) *N*-(3-chloro-2-fluorophenyl)-6-({1-[(3,5-dimethylisoxazol-4-yl)carbonyl]piperidin-4-yl}oxy)-7-methoxyquinazolin-4-amine;

~~(8)*N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-{[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]oxy}quinazolin-4-amine;~~

~~(9) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]oxy}quinazolin-4-amine;~~

~~(10) *N*-(3-chloro-2-fluorophenyl)-6-{[1-(2-furoyl)piperidin-4-yl]oxy}-7-methoxyquinazolin-4-amine;~~

~~(11)~~(8) *N*-(3-chloro-2-fluorophenyl)-7-{[1-(isoxazol-5-ylcarbonyl)piperidin-4-yl]oxy}-6-methoxyquinazolin-4-amine;

~~(12)~~(9) *N*-(3-chloro-2-fluorophenyl)-6-methoxy-7-({1-[(3-methylisoxazol-5-yl)acetyl]piperidin-4-yl}oxy)quinazolin-4-amine;

~~(13) *N*-(3-chloro-2-fluorophenyl)-7-{[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]oxy}-6-methoxyquinazolin-4-amine;~~

~~(14) *N*-(3-chloro-2-fluorophenyl)-7-{[1-(2-furoyl)piperidin-4-yl]oxy}-6-methoxyquinazolin-4-amine;~~

~~(15) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-{[(3*R*)-1-(2-thienylacetyl)piperidin-3-yl]oxy}quinazolin-4-amine;~~

~~(16) *N*-(3-chloro-2-fluorophenyl)-6-{[(3*R*)-1-isonicotinoylpiperidin-3-yl]oxy}-7-methoxyquinazolin-4-amine;~~

~~(17) 6-({(3*R*)-1-[(2-aminopyridin-3-yl)carbonyl]piperidin-3-yl}oxy)-*N*-(3-chloro-2-fluorophenyl)-7-methoxyquinazolin-4-amine;~~

~~(18) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-{[(3*R*)-1-(1*H*-pyrrol-2-ylcarbonyl)piperidin-3-yl]oxy}quinazolin-4-amine;~~

~~(19) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-{[(3*R*)-1-(2-thienylcarbonyl)piperidin-3-yl]oxy}quinazolin-4-amine;~~

~~(20) *N*-(3-chloro-2-fluorophenyl)-6-{[(3*R*)-1-(2-furoyl)piperidin-3-yl]oxy}-7-methoxyquinazolin-4-amine;~~

~~(21) *N*-(3-chloro-2-fluorophenyl)-6-{[(3*R*)-1-(3-furoyl)piperidin-3-yl]oxy}-7-methoxyquinazolin-4-amine;~~

~~(22) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-{[(3*R*)-1-(3-thienylcarbonyl)piperidin-3-yl]oxy}quinazolin-4-amine;~~

~~(23)*N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-{[(3*R*)-1-(3-thienylacetyl)piperidin-3-yl]oxy}quinazolin-4-amine;~~

~~(24)*N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-({(3*R*)-1-[(1-methyl-1*H*-pyrrol-2-yl)carbonyl]piperidin-3-yl}oxy)quinazolin-4-amine;~~

~~(25)*N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-({(3*R*)-1-[(4-nitro-1*H*-pyrazol-1-yl)acetyl]piperidin-3-yl}oxy)quinazolin-4-amine;~~

~~(26)~~(10) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-({(3*R*)-1-[(3-methylisoxazol-5-yl)acetyl]piperidin-3-yl}oxy)quinazolin-4-amine;

~~(27)~~(11) *N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-{[(3*R*)-1-(4-{*N*,*N*-dimethylcarbamoyl}-1*H*-pyrazol-1-ylacetyl)piperidin-3-yl]oxy}quinazolin-4-amine; and

~~(28)*N*-(3-chloro-2-fluorophenyl)-7-methoxy-6-{[(3*R*)-1-(4-cyano-1*H*-pyrazol-1-ylacetyl)piperidin-3-yl]oxy}quinazolin-4-amine;~~

~~(29)4-({4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-*N*-phenylpiperidine-1-carboxamide;~~

~~(30)*N*-Benzyl-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidine-1-carboxamide;~~

~~(31)4-({4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-*N*-[4-(dimethylamino)phenyl]piperidine-1-carboxamide;~~

~~(32)4-({4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-*N*-(2-phenylethyl)piperidine-1-carboxamide;~~

~~(33)4-({4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-*N*-(3,4-dimethoxyphenyl)piperidine-1-carboxamide;~~

~~(34)4-({4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-*N*-(3-fluorophenyl)piperidine-1-carboxamide;~~

~~(35)~~(12) 4-({4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-*N*-(3,5-dimethylisoxazol-4-yl)piperidine-1-carboxamide.~~;~~

~~(36)4-({4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-*N*-2-thienylpiperidine-1-carboxamide;~~

~~(37)4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-*N*-3-thienylpiperidine-1-carboxamide.~~

Claim 32 (**currently amended**): A process for the preparation of a quinazoline derivative of the Formula I as defined in any one of the preceding claims, which process comprises either

**Process (a)** reacting a compound of the Formula II:




Formula II

wherein $R^3$ and a are as defined in claim 1 and one of $R^{1a'}$ or $R^{1b'}$ is hydroxy and the other is a group $R^1$ as defined in claim 1 in relation to formula (I), except that any functional group is protected if necessary,

with a compound of the Formula III:

$$Q^2\text{-}X^1\text{-}Z\text{-}Q^1\text{-}X^2\text{-}Lg$$

Formula III

wherein $Q^1$, $Q^2$, Z, $X^2$ and $X^1$ have any of the meanings defined in claim 1, except that any functional group is protected if necessary and Lg is a displaceable group:

**Process (b)** modifying a substituent in or introducing a substituent into another quinazoline derivative of Formula I or a pharmaceutically acceptable salt thereof as defined in claim 1, except that any functional group is protected if necessary;

**Process (c)** reacting a compound of the Formula II as defined in respect of process (a) above with a compound of the Formula III as defined in process (a) except Lg is OH under Mitsunobu conditions,

**Process (d)** for the preparation of those compounds of the Formula I wherein the group $R^1$ is a hydroxy group by the cleavage of a quinazoline derivative of the Formula I wherein $R^1$ is a (1-6C)alkoxy group;

**Process (e)** for the preparation of those compounds of the Formula I wherein $R^1$ is a (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, or a group of the formula :

$$Q^4\text{-}X^3\text{-}$$

wherein $X^3$ is O and $Q^4$ is as defined in claim 5, by the reaction of a compound of the Formula I wherein $R^1$ is OH, except that any functional group is protected if necessary, with a compound of the formula $R^{1'}$-Lg, wherein $R^{1'}$ is a (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, or a group $Q^4$ where $Q^4$ is as defined in claim 5, and Lg is a displaceable group;

**Process (f)** for the preparation of those compounds of the Formula I wherein $Q^1$, $Q^2$ contains or $R^1$ is or contains a (1-6C)alkoxy or substituted (1-6C)alkoxy group or a (1-6C)alkylamino or substituted (1-6C)alkylamino group, the alkylation of a quinazoline derivative of the Formula I wherein $Q^1$, $Q^2$ contains or $R^1$ is or contains a hydroxy group or a primary or secondary amino group as appropriate;

**Process (g)** for the preparation of those compounds of the Formula I wherein $R^1$ is substituted by a group T, wherein T is selected from (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoylamino, (1-6C)alkylthio, (1-6C)alkylsulfinyl and (1-6C)alkylsulfonyl, the reaction of a compound which is of formula (I) except that the group $R^1$ is replaced with a group $R^{1''}$-Lg wherein Lg is a displaceable group, and $R^{1''}$ is a group $R^1$ except that it has Lg in place of the group T , and further that any functional group is protected if necessary, with a compound of the formula TH, wherein T is as defined above except that any functional group is protected if necessary;

**Process (h)** by reacting a compound of the formula VI:



formula VI

wherein $R^{1a}$ and $R^{1b}$ have any of the meanings defined in claim 1 except that any functional group is protected if necessary and Lg is a displaceable group,

with an aniline of the formula VII:




formula VII

wherein $R^3$ and a have any of the meanings defined in claim 1, except that any functional group is protected if necessary, and wherein the reaction is conveniently performed in the presence of a suitable acid, or

**Process (i)** for the preparation of those compounds of the Formula I wherein $Q^1$ is a nitrogen containing heterocyclyl group linked to the group Z by a ring nitrogen, the coupling of a compound of the Formula I as defined in claim 1, except that the group of sub-formula (i) is a group of sub-formula (x) H-$Q^1$-$X^2$-O-, and any functional group is protected if necessary, with a compound of formula $Q^2$-$X^1$-Z-Lg, wherein Z, $Q^2$ and $X^1$ are as defined in claim 1 and Lg is a leaving group;

**Process (j)** for the preparation of those compounds of the Formula I define in claim 1 wherein $Q^1$ is a nitrogen containing heterocyclyl group linked to the -Z- group by a ring nitrogen, and Z is a group of formula –$NR^{10}$-C(O)-; said process comprising the coupling of a compound of the Formula I, except that the group of sub-formula (i) is a group of sub-formula (x) H-$Q^1$-$X^2$-O-, and any functional group is protected if necessary, with a compound of formula $Q^2$-$X^1$-N=C=O, wherein $Q^2$ and $X^1$ are as defined in claim 1;

and whereafter any protecting group that is present is removed ~~by conventional means~~.

Claim 33 (**currently amended**): The ~~A~~ process according to claim 32, wherein Lg is a leaving group selected from hydroxyl, chloro or bromo.

Claim 34 (**currently amended**): A pharmaceutical composition which comprises a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined in claim 1 ~~any one of claims 1 to 31~~ in association with a pharmaceutically-acceptable diluent or carrier.

Claims 35-36 (**cancelled**).

Claim 37 (**currently amended**): A method for producing an anti-proliferative effect in a warm-blooded animal in need of such treatment which comprises administering to said animal a quinazoline derivative of the Formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 ~~any one of claims 1 to 31~~.